Chart of Day: Viking Therapeutics Almost a $100 Stock – 3/5

On February 20, we noted:

“While the obesity drug stock has already exploded, it could see higher highs. At the moment, Viking Therapeutics and its potential treatment for obesity – VK2735, has already shown a mean weight loss of up to 18 pounds from baseline. The company also initiated Phase 1 clinical study to evaluate a novel oral formulation of VK2735.”

At the time, VKTX traded at just $35 a share.

Today, it’s up to $93.53 and rocketing higher. Not only is the company emerging as a strong obesity drug contender, it may even be an acquisition target.


According to CNBC, “Some Wall Street analysts said Viking’s experimental obesity treatment may be ‘best-in-class.’ In a midstage trial, an injectable version of Viking’s drug appeared to promote even greater weight loss than Eli Lilly’s Zepbound. Analysts were particularly impressed by the weight patients lost after they took the highest dose of Viking’s drug. Those who received a weekly 15 milligram dose of the treatment lost 13.1% of their body weight on average after 13 weeks compared to those who took the placebo.”

Should VKTX see further trial success, the stock could see higher highs.

If you bought shares on our initial mention, congratulations on the win so far.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.